Evodiamine protects against lung ischemia–reperfusion injury by attenuating SYK-associated TLR4/NLRP3 inflammasome activation and ferroptosis-related injury signatures
Pulmonary Pharmacology & Therapeutics · 2026-06 · 93 · 102421
DOI: 10.1016/j.pupt.2026.102421 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pulmonary Pharmacology & Therapeutics, 2026-06. Verfasst von Wei Peng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary and Critical Care Medicine, The People's Hospital of Liaoning Province, Liaoning, 110016, China. Hauptthemen laut MEDLINE: Reperfusion Injury, Quinazolines, Acute Lung Injury. Die Arbeit nennt 35 Literaturangaben. Gefördert von: Shenyang Municipal Bureau of Science and Technology.
Abstract (Originalsprache)
Lung ischemia-reperfusion (I/R) injury is a major driver of acute lung dysfunction after procedures such as lung transplantation, yet effective pharmacological strategies remain limited. We evaluated whether evodiamine (EVO) mitigates lung I/R injury and explored potential mechanisms. Male C57BL/6 mice underwent left pulmonary hilar occlusion (60 min) followed by reperfusion (120 min) and received EVO, the SYK inhibitor BAY61-3606, or the combination. Compared with I/R alone, treatment reduced histopathological damage, inflammatory cytokine expression, apoptosis, and ferroptosis-associated marker changes (iron overload, PTGS2 induction, and loss of GPX4/SLC7A11). EVO was associated with decreased activation of the SYK/TLR4/NLRP3 inflammasome axis, and BAY61-3606 recapitulated several protective effects. Because the mechanistic inference is based on pharmacological inhibition, these findings support-rather than definitively prove-SYK-linked TLR4/NLRP3 signaling as an important node in EVO-mediated protection. Together, the data suggest that evodiamine alleviates acute lung I/R injury in part by restraining inflammatory signaling and modulating ferroptosis-related markers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pulmonary and Critical Care Medicine, The People's Hospital of Liaoning Province, Liaoning, 110016, China.
- Department of Emergency, The People's Hospital of Liaoning Province, Liaoning, 110016, China.
- Department of Pulmonary and Critical Care Medicine, Liaoning Fangda General Hospital, Liaoning, 110172, China.
- Shenyang Medical College, No. 146, Huanghe North Street, Shenyang, Liaoning, 110034, China.
- Department of Pulmonary and Critical Care Medicine, The People's Hospital of Liaoning Province, Liaoning, 110016, China. Electronic address: d1008@lnph.com.
Förderung
- Shenyang Municipal Bureau of Science and Technology
Zitieren
APA
Peng, W., Ge, B., Zhang, R., Liu, Y., Tong, C., & Dong, C. (2026). Evodiamine protects against lung ischemia–reperfusion injury by attenuating SYK-associated TLR4/NLRP3 inflammasome activation and ferroptosis-related injury signatures. Pulmonary Pharmacology & Therapeutics, 93, 102421. https://doi.org/10.1016/j.pupt.2026.102421
Vancouver
Peng W, Ge B, Zhang R, Liu Y, Tong C, Dong C. Evodiamine protects against lung ischemia–reperfusion injury by attenuating SYK-associated TLR4/NLRP3 inflammasome activation and ferroptosis-related injury signatures. Pulmonary Pharmacology & Therapeutics. 2026;93:102421. doi:10.1016/j.pupt.2026.102421
BibTeX
@article{Peng2026,
author = {Peng, Wei and Ge, Baiping and Zhang, Rui and Liu, Yunen and Tong, Changci and Dong, Chenguang},
title = {Evodiamine protects against lung ischemia–reperfusion injury by attenuating SYK-associated TLR4/NLRP3 inflammasome activation and ferroptosis-related injury signatures},
journal = {Pulmonary Pharmacology & Therapeutics},
year = {2026},
volume = {93},
pages = {102421},
doi = {10.1016/j.pupt.2026.102421}
}
EUVIMED